BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30823903)

  • 21. IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
    Miyake Y; Fujii K; Nakamaura T; Ikegaya N; Matsushita Y; Gobayashi Y; Iwashita H; Udaka N; Kumagai J; Murata H; Takemoto Y; Yamanaka S; Ichimura K; Tateishi K; Yamamoto T
    J Neuropathol Exp Neurol; 2021 Feb; 80(3):247-253. PubMed ID: 33432322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
    Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
    Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 25. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
    Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
    [No Abstract]   [Full Text] [Related]  

  • 26. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
    Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
    BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.
    Kim SW; Park BJ; Kim HS; Na K
    In Vivo; 2021; 35(2):921-927. PubMed ID: 33622884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.
    Garton ALA; Kinslow CJ; Rae AI; Mehta A; Pannullo SC; Magge RS; Ramakrishna R; McKhann GM; Sisti MB; Bruce JN; Canoll P; Cheng SK; Sonabend AM; Wang TJC
    J Neurosurg; 2020 May; 134(5):1357-1367. PubMed ID: 32384274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
    Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
    Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare occurrence of IDH2 mutation in adolescent oligodendroglioma with 1p/19q co-deletion: a case report.
    Rao S; Sivakoti S; Arivazhagan A; Santosh V
    Childs Nerv Syst; 2020 Dec; 36(12):3109-3113. PubMed ID: 32296936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
    Cairncross JG; Wang M; Jenkins RB; Shaw EG; Giannini C; Brachman DG; Buckner JC; Fink KL; Souhami L; Laperriere NJ; Huse JT; Mehta MP; Curran WJ
    J Clin Oncol; 2014 Mar; 32(8):783-90. PubMed ID: 24516018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification.
    Akagi Y; Yoshimoto K; Hata N; Kuga D; Hatae R; Amemiya T; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
    Brain Tumor Pathol; 2018 Apr; 35(2):81-89. PubMed ID: 29569163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
    Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
    Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
    J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
    Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
    Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.